pharmaceuticals

145922793

Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings

While most of the top stocks in the S&P 500 are winding up the third-quarter reporting season, the specialty pharmaceutical stocks are ready to come from the on-deck circle and ...
Read Full Story »
Money background. Close-up.

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences Inc. (NASDAQ: GILD) reported its third-quarter results after the market close on Monday as $1.84 in earnings per share and $6.04 billion in revenue. That was against Thomson ...
Read Full Story »
biotech

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its third-quarter earnings after the U.S. markets close on Tuesday. Thomson Reuters has consensus estimates of $1.92 in earnings per shares ...
Read Full Story »
Pills

Amgen Posts 52-Week High, Beats It Again After Earnings

Drug maker Amgen Inc. (NASDAQ: AMGN) reported third-quarter 2014 results after markets closed Monday afternoon. The biotech company reported quarterly adjusted diluted earnings per share (EPS) of $2.30 and revenues ...
Read Full Story »
152498601

Pain Therapeutics and Durect Stung by Pfizer Move

Pain Therapeutics Inc. (NASDAQ: PTIE) shares dropped significantly in Monday’s trading on news that Pfizer Inc. (NYSE: PFE) had discontinued its agreement to develop and commercialize Pain’s Remoxy extended release ...
Read Full Story »
fda_logo

Sarepta Faces Major Hurdle, and Not From Ebola

In non-Ebola related news, Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot. The stock ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
merck

Merck Earnings Look Very Mixed in Major Restructuring

Merck & Co. Inc. (NYSE: MRK) reported its third-quarter results Monday morning as $0.90 in earnings per share and $10.6 billion in revenue. That was against Thomson Reuters consensus earnings ...
Read Full Story »
Pfizer

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

A Pfizer Inc. (NYSE: PFE) press release on Thursday evening was honestly given the wrong title by the company's investor relations department. The new release titled "Pfizer Declares 26-Cent Fourth-Quarter ...
Read Full Story »
135093244

Companies That Benefit as Sexually Transmitted Disease Cases Keep Growing

Although it is a subject many investors would like to avoid, for obvious reasons, the growth in the number of sexually transmitted diseases (or STDs, as they are called) is ...
Read Full Story »
Pills

3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion

For now, while the benefit for American corporations to buy or merge and move overseas may be over, as evidenced by AbbVie cancelling its merger with Shire Pharmaceutical, that doesn't ...
Read Full Story »
Merger

NewLink Scores Major Partners With Roche’s Genentech

NewLink Genetics Corp. (NASDAQ: NLNK) announced that it has entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's ...
Read Full Story »
Ebola Virus

Ebola Stocks Move in Different Directions

Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brings a mixed view for this group. Allied Healthcare Products Inc. (NASDAQ: AHPI) in Friday ...
Read Full Story »
Ebola Virus

Ebola Stocks on the Move

Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears. Ultimately these fears and some hopes of potential contracts or increased ...
Read Full Story »
Ebola Virus

Ebola Fears Driving Ebola Stock Winners

Fears of Ebola have plagued the United States since late September, and some biotech companies have capitalized on this fear. These fears and some hopes of potential contracts or increased ...
Read Full Story »